Clinical Trials - October 19, 2020
Ultimovacs announces Phase I data
Ultimovacs has announced five-year overall survival data from the Phase I trial evaluating UV1 as maintenance therapy in patients with non-small cell lung cancer. The results confirm achievement of the primary endpoints of safety and tolerability and indicate encouraging initial signals of long-term survival benefit. “Ultimovacs has established a growing body of clinical data demonstrating […]
Clinical Trials - October 1, 2020
Ultimovacs announces positive trial results
Ultimovacs has announced positive results from the first cohort of 20 patients in its ongoing US-based Phase I clinical trial evaluating the company’s lead candidate, UV1, in combination with PD-1 checkpoint inhibitor, pembrolizumab, as a first line treatment in patients with metastatic malignant melanoma. The results confirm achievement of the primary endpoints of safety and […]
Clinical Trials - August 27, 2020
Ultimovacs completes patient enrollment in Phase I trial
Ultimovacs has announced that patient enrollment has been completed in the ongoing US-based Phase I clinical trial testing Ultimovacs’ lead candidate, UV1, in combination with pembrolizumab as first line treatment in patients with metastatic malignant melanoma. The study was designed to assess the safety and tolerability of UV1 combined with checkpoint inhibitor pembrolizumab and to […]
Financing - June 15, 2019
Ultimovacs enters the Oslo Stock Exchange
The Norwegian cancer vaccine company has raised NOK 370 million and entered the Oslo Stock Exchange on Monday 3 June 2019. Several interested parties have now become shareholders in the company, totalling approximately 1 500 shareholders, reports Oslo Cancer Cluster. “It is good for the Norwegian health industry and for Ultimovacs when national and international […]
Biotech Business - January 29, 2016
PCI Biotech and Ultimovacs collaborates
PCI Biotech and Ultimovacs are initiating a preclinical research collaboration. The purpose of the collaboration is to utilise the companies’ complementary scientific platforms to explore potential synergies. Both companies are situated in the Oslo Cancer Cluster Incubator. The partnership is governed by a preclinical research collaboration agreement. In brief, the preclinical research collaboration will evaluate technology […]
Funding - December 3, 2014
Oslo Cancer Cluster Names Research Grant Winners
Oslo Cancer Cluster recently named three winners in a competition seeking collaborative projects involving immuno-oncology. The three, BerGen Bio, Targovax and Ultimovacs each will receive MNOK 0,4 from Innovation Norway. BerGenBio will use the award to prove that Axl kinase inhibition may provoke an anti-tumor immune response, working with partners from the University of Bergen, Oslo, […]
